The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products.

In this webinar the recording of Carl Balibar’s presentation ‘Mining of chemical libraries for new antibacterials’ (original webinar on 21 May) will be followed by another live Q&A session with Carl.

Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) will discuss screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.

Speakers:
Carl Balibar, Principal Scientist, Merck Research Laboratories

Moderator:
Benjamin Blasco, Discovery Senior Project Manager, GARDP

Register here for this live webinar.